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wavelengths until the PSS is reached. Black arrows indicate the changes in the absorption upon trans-cis-isomerization. Dotted black arrows indicate isosbestic points. Middle panel. Cycle performance. Changes in absorption at  max of the trans-isomer were measured during alternate irradiation with the indicated wavelengths. Lower panel. Thermal half-life determined at  max of the trans-isomer. Figure S3 : UV-vis absorption spectroscopic characterization of compound 12a measured at 50 µM in DMSO. As the cis-trans back isomerization is not triggerable by irradiation with light no cycle performance was recorded. Upper panel. UV-vis absorption spectrum upon continuous irradiation with the indicated wavelength until the PSS is reached. Black arrow indicates the change in the absorption upon trans-cis-isomerization. Lower panel. Thermal half-life determined at  max of the trans-isomer. Figure S4 : UV-vis absorption spectrum of non-photochromic compound 12b. Figure S5 : UV-vis absorption spectroscopic characterization of compound 16a measured at 50 µM in DMSO (left) and phosphate buffer + 0.1% DMSO (right), respectively. Upper panel. UV-vis absorption spectra upon continuous irradiation with the indicated wavelengths until the PSS is reached. Black arrows indicate the changes in the absorption upon trans-cis-isomerization. Dotted black arrows indicate isosbestic points. Middle panel. Cycle performances. Changes in absorption at  max of the trans-isomer were measured during alternate irradiation with the indicated wavelengths. Lower panel. Thermal half-lives determined at  max of the trans-isomer. Figure S6 : UV-vis absorption spectroscopic characterization of compound 16b measured at 50 µM in DMSO (left) and phosphate buffer + 0.1% DMSO (right), respectively. Upper panel. UV-vis absorption spectra upon continuous irradiation with the indicated wavelengths until the PSS is reached. Black arrows indicate the changes in the absorption upon trans-cis-isomerization. Dotted black arrows indicate isosbestic points. Middle panel. Cycle performances. Changes in absorption at  max of the trans-isomer were measured during alternate irradiation with the indicated wavelengths. Lower panel. Thermal half-lives determined at  max of the trans-isomer.
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Figure S7: UV-vis absorption spectroscopic characterization of compound 16c measured at 50 µM in DMSO (left) and phosphate buffer + 0.1% DMSO (right), respectively. As the cis-trans back isomerization is not triggerable by irradiation with light no cycle performances were recorded. Upper panel. UV-vis absorption spectra upon continuous irradiation with the indicated wavelength until the PSS is reached. Black arrows indicate the change in the absorption upon trans-cisisomerization. Lower panel. Thermal half-lives determined at  max of the trans-isomer. Figure S8 : UV-vis absorption spectroscopic characterization of compound 16d measured at 50 µM in DMSO (left) and phosphate buffer + 0.1% DMSO (right), respectively. As the cis-trans back isomerization is not triggerable by irradiation with light no cycle performances were recorded. Upper panel. UV-vis absorption spectra upon continuous irradiation with the indicated wavelength until the PSS is reached. Black arrows indicate the change in the absorption upon trans-cis-isomerization. Dotted black arrows indicate isosbestic points. Lower panel. Thermal half-lives determined at  max of the trans-isomer. Figure S9 : UV-vis absorption spectroscopic characterization of compound 23 measured at 50 µM in DMSO. Upper panel. UV-vis absorption spectrum upon continuous irradiation with the indicated wavelengths until the PSS is reached. Black arrows indicate the changes in the absorption upon trans-cis-isomerization. Dotted black arrows indicate isosbestic points. Middle panel. Cycle performance. Changes in absorption at  max of the trans-isomer were measured during alternate irradiation with the indicated wavelengths. Lower panel. Thermal half-life determined at  max of the trans-isomer. was selected and mounted on a MITIGEN holder with inert oil on a SuperNova, Single source at offset/far, Atlas diffractometer. The crystal was kept at T = 123 K during data collection. Using Olex2 (Dolomanov et al., 2009) [S1] , the structure was solved with the ShelXT [S2] structure solution program, using the Intrinsic Phasing solution method. The model was refined with version 2016/6 of ShelXL [S3] using Least Squares minimisation. support on an GV1000, TitanS2 diffractometer. The crystal was kept at a steady T = 123.01(13) K during data collection. The structure was solved with the ShelXT [S2] structure solution program using the Intrinsic Phasing solution method and by using Olex2 (Dolomanov et al., 2009) [S1] as the graphical interface. The model was refined with version 2016/6 of ShelXL [S3] using Least Squares minimisation. [S13] were synthesized following adapted reported procedures.
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Methods
Chemistry
(E)-2-(p-Tolyldiazenyl)quinoxaline (5a).
This compound was synthesized via an adapted literature reported procedure [S5] . Nitrosoquinoxaline 3 (479 mg, 3.0 mmol, 1.0 equiv) and p-toluidine (4a, 362 mg, 3.4 mmol, 1.1 equiv) were suspended in acetic acid (10 mL), refluxed for 10 min and stirred at room temperature for additional 16 hours. Purification by flash column chromatography using CH 2 Cl 2 as the eluent afforded the desired product as red solid (565 mg, 2.3 mmol, 76%). 
(E)-2-((3-Chloro-2-methylphenyl)diazenyl)quinoxaline (5b).
This compound was synthesized via an adapted literature reported procedure [S5] . Nitrosoquinoxaline 3 (479 mg, 3.0 mmol, 1.0 equiv) and S28 aniline (4b, 479 mg, 3.4 mmol, 1.1 equiv) were mixed in acetic acid (10 mL) and heated to reflux for 10 min. The mixture was then heated at 50 °C for additional 16 hours. Purification by flash column chromatography using CH 2 Cl 2 as the eluent afforded the target compound as red solid (40% -3-(p-tolyldiazenyl)quinoxaline (12a) and (E)-1-methyl-3-(p-tolyldiazenyl)quinoxalin-2(1H)-one (12b) . These compounds were synthesized via an adapted literature reported procedure [S14] . Compound 11 (359 mg, 1.36 mmol, 1.0 equiv) and potassium carbonate (188 mg, 1.36 mmol, 1.0 equiv) were suspended in DMF (6 mL). Then methyl iodide (193 mg, 1.36 mmol, 1.0 equiv) was added and the mixture stirred at room temperature for 16 hours. Water (2 mL/mmol) was added to the mixture and the aqueous layer extracted with ethyl acetate for three times. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and the solvent evaporated. Purification by flash column chromatography using petroleum ether/ethyl acetate 1:1 as eluent afforded the products 12a and 12b. Characterization of 12a. and n-BuOH (5 mL) were mixed and stirred at 150 °C for 16 hours. The reaction mixture was cooled to room temperature and exposed to pure oxygen (balloon) for 24 hours. Purification by flash column chromatography using CH 2 Cl 2 as the eluent afforded the desired product as red solid (151 mg, 0.6 mmol, 53%). (E)-6-((2-Chlorophenyl)diazenyl)-9H-purine (16b). This compound was synthesized via an adapted literature reported procedure [S15] . 6-Chloro-9-isopropyl-9H-purine (371 mg, 2.4 mmol, 1.0 equiv), o-chlorophenylhydrazine (411 mg, 2.9 mmol, 1.2 equiv), DIPEA (1.55 g, 12 mmol, 5.0 equiv) and nBuOH (16 mL) were mixed and stirred in a glass vial at 150 °C for 16 hours. The reaction mixture was cooled to room temperature and exposed to pure oxygen (balloon) for 24 hours. The solvent was removed and the product purified by flash column chromatography using CH 2 Cl 2 + 5% MeOH to afford 16b as red solid (417 mg, 1.6 mmol, 67%). 
(E)-2-Methoxy
S29
(E)-6-(Naphthalen-1-yldiazenyl)-9H-purine (16c). This compound was synthesized via an adapted literature reported procedure [S15] . A mixture of chloroadenine 15a (93.0 mg, 0.60 mmol, 1.0 equiv), hydrazine 14b (114 mg, 0.72 mmol, 1.2 equiv) and DIPEA (388 mg, 0.52 mL, 3.0 mmol, 5.0 equiv) in nbutanol (4.0 mL) was stirred at 150 °C for 16 hours. After cooling to room temperature, the solution was exposed to an oxygen atmosphere (balloon) for 24 hours. The product was purified by column chromatography using CH 2 Cl 2 + 5% MeOH as eluent and subsequent preparative HPLC ( (E)-9-Methyl-6-(naphthalen-1-yldiazenyl)-9H-purine (16d). This compound was synthesized via an adapted literature reported procedure [S15] . A mixture of methylated chloroadenin 15b (101 mg, 0.60 mmol, 1.0 equiv), hydrazine 14b (114 mg, 0.72 mmol, 1.2 equiv) and DIPEA (388 mg, 0.52 mL, 3.0 mmol, 5.0 equiv) in n-butanol (4.0 mL) was stirred at 150 °C for 16 hours. After cooling to room temperature, the solution was exposed to an oxygen atmosphere (balloon) for 24 hours. The product was purified by column chromatography using CH 2 Cl 2 + 5% MeOH as eluent and subsequent preparative HPLC (gradient 0-20 min: MeCN/H 2 O 10:90 to 98:2) and afforded the methylated azoadenine 16d as red solid (t R = 12.91 min, 130 mg, 0.45 mmol, 75%). (E)-6-((4-(Phenyldiazenyl)benzyl)thio)-7H-purine (23). This compound was synthesized via an adapted literature reported procedure [S16] . A solution of chloromethylated azobenzene 21 (800 mg, 3.5 mmol, 1.1 equiv) in DMF (10 mL) was added to a solution of 6-mercaptopurine 22 (151 mg, 3.2 mmol, 1.0 equiv) in 2 M NaOH (10 mL) and the mixture stirred at room temperature for 3 hours. The solvent was evaporated and the product purified by flash column chromatography using CH 2 Cl 2 + 5% MeOH as the eluent. Evaporation of the solvent afforded the desired product as orange solid (215 mg, 0.62 mmol, 18%). (E)-4-(Phenyldiazenyl)-N-(9H-purin-6-yl)benzamide (28). This compound was synthesized via an adapted literature reported procedure [S17] . Chlorocarbonylazobenzene 26 (636 mg, 2.6 mmol, 1.1 equiv) was added dropwise over 30 min to a stirred suspension of adenine 27 (324 mg, 2.4 mmol, 1.0 equiv) in dry pyridine and stirring was continued for two hours at 100 °C. The mixture was cooled to room temperature and stirred for additional 16 hours. The reaction was quenched with methanol and the solvents were removed under reduced pressure. Purification by column chromatography using CH 2 Cl 2 as the eluent afforded the desired product as orange solid (684 mg, 2.0 mmol, 83%). Electrophysiological recordings Whole-cell patch-clamp recordings were held at room temperature (20-25 o C) using an EPC-9 amplifier (HEKA Elektronik, Germany). Cells were continuously superfused with external solution containing (mM): NaCl 140, CaCl 2 2, KCl 2.8, MgCl 2 4, HEPES 20, glucose 10; pH 7.4; 320-330 mOsm. Intracellular solution used for filling recording patch pipettes contained (mM): KCl 140, MgCl 2 2, MgATP 2, BAPTA (tetrapotassium salt) 2; pH 7.3; 290 mOsm. Recording pipettes were pulled from borosilicate glass capillaries (Harvard Apparatus Ltd, USA) and had resistances of 5-10 MOhm. Rapid replacement of solutions was provided by fast application system (SF 77A Perfusion Fast-Step, Warner, USA), placed 40-50 µm above the recorded cell. Cells with low input resistance (<150 MOhm) and a rapid run-down (>30% with repetitive application) were excluded from analysis. The agonist 5-HT for the activation was applied alone or mixed with studied compounds during 5 s. Irradiation with the light of 455 nm or 530 nm was provided by LEDs (Thorlabs) placed at the distance of 4-5 cm from the studied cells.
